Amalyte Pharmaceuticals LLC

Amalyte and Meiji Enter Into a License, Development and Commercialization Agreement on AM3301 and a Novel Class of Anti-Inflammatory Compounds

Published in Managed Care Business Week, June 23rd, 2009

Amalyte Pharmaceuticals LLC (Amalyte), a member of the Kemin group of companies, has announced it has entered into a worldwide strategic alliance with Meiji Seika Kaisha Ltd. (Meiji) to discover, develop and commercialize a lead compound, ME3301 (now AM3301), and novel class of dual-acting anti-inflammatory compounds for a variety of human health applications.

Under the terms of the agreement, Amalyte will have exclusive rights to develop and commercialize collaboration products worldwide, except in Japan and several Asian countries where Meiji has a development and commercialization option for all products arising from the collaboration. The companies will co-market...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Managed Care Business Week

Source: Managed Care Business Week (2009-06-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry